Evidence map›Paper›PMID 34959543›Full record

ArticlePathogens (Basel, Switzerland)2021

Treatment of Pregnant Women with Ivermectin during Mass Drug Distribution: Time to Investigate Its Safety and Potential Benefits.

Astrid Christine Erber, Esther Ariyo, Piero Olliaro, Patricia Nicolas, Carlos Chaccour, Robert Colebunders

Open access · goldAbstract read
In one paragraph

Article in Pathogens (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 4 countries.

Astrid Christine ErberDepartment of Epidemiology, Center for Public Health, Medical University of Vienna, 1090 Vienna, Austria.ORCID 0000-0001-5252-9676
Esther AriyoCenter for Population Family Health, University of Antwerp, 2600 Antwerp, Belgium.
Piero OlliaroCentre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7FZ, UK.
Patricia NicolasInstituto de Salut Global Barcelona, Hospital Clínic-Universitat de Barcelona, 08036 Barcelona, Spain.
Carlos ChaccourInstituto de Salut Global Barcelona, Hospital Clínic-Universitat de Barcelona, 08036 Barcelona, Spain.ORCID 0000-0001-9812-050X
Robert ColebundersGlobal Health Institute, University of Antwerp, 2610 Antwerp, Belgium.ORCID 0000-0002-1919-1340
University of Antwerp · BEUniversity of Oxford · GBCentro de Investigación Biomédica en Red · ESUniversitat de Barcelona · ES

Funding

European Research Council ERC 671055
6 · The paper itself

Abstract

To date, pregnant women are excluded from programmes delivering community-directed treatment of ivermectin (CDTI) for onchocerciasis and preventive chemotherapy of other helminthiases because of concerns over ivermectin safety during pregnancy. This systematic exclusion sustains an infection reservoir at the community level and deprives a vulnerable population from known benefits-there are indications that treating

Indexed as

epilepsyivermectinnodding syndromeonchocerciasispregnancyregistrysafetytrial

Identifiers

PMID34959543
PMCPMC8703637
OpenAlexW4200099720

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.